跳转至内容
Merck
CN
  • Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.

Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.

Genome biology (2014-08-28)
Rosalie Fisher, Stuart Horswell, Andrew Rowan, Maximilian P Salm, Elza C de Bruin, Sakshi Gulati, Nicholas McGranahan, Mark Stares, Marco Gerlinger, Ignacio Varela, Andrew Crockford, Francesco Favero, Virginie Quidville, Fabrice André, Carolina Navas, Eva Grönroos, David Nicol, Steve Hazell, David Hrouda, Tim O'Brien, Nik Matthews, Ben Phillimore, Sharmin Begum, Adam Rabinowitz, Jennifer Biggs, Paul A Bates, Neil Q McDonald, Gordon Stamp, Bradley Spencer-Dene, James J Hsieh, Jianing Xu, Lisa Pickering, Martin Gore, James Larkin, Charles Swanton
摘要

Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution. We perform whole exome sequencing on four clear cell renal cell carcinomas removed from both kidneys of a patient with a germline VHL mutation. We report that tumors arising in this context are clonally independent and harbour distinct secondary events exemplified by loss of chromosome 3p, despite an identical genetic background and tissue microenvironment. We propose that divergent mutational and copy number anomalies are contingent upon the nature of 3p loss of heterozygosity occurring early in tumorigenesis. However, despite distinct 3p events, genomic, proteomic and immunohistochemical analyses reveal evidence for convergence upon the PI3K-AKT-mTOR signaling pathway. Four germline tumors in this young patient, and in a second, older patient with VHL syndrome demonstrate minimal intra-tumor heterogeneity and mutational burden, and evaluable tumors appear to follow a linear evolutionary route, compared to tumors from patients with sporadic clear cell renal cell carcinoma. In tumors developing from a germline VHL mutation, the evolutionary principles of contingency and convergence in tumor development are complementary. In this small set of patients with early stage VHL-associated tumors, there is reduced mutation burden and limited evidence of intra-tumor heterogeneity.

材料
货号
品牌
产品描述

Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
甘氨酸, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
甘氨酸, suitable for electrophoresis, ≥99%
Sigma-Aldrich
3-吗啉丙磺酸, ≥99.5% (titration)
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
甘氨酸, BioUltra, for molecular biology, ≥99.0% (NT)
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
3-吗啉丙磺酸, BioPerformance Certified, suitable for cell culture, ≥99.5% (titration)
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
甘氨酸, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
SAFC
甘氨酸
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
USP
木精, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
3-吗啉丙磺酸, BioXtra, ≥99.5% (titration)
Supelco
甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
USP
甘氨酸, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Supelco
甲醇, analytical standard
Sigma-Aldrich
甘氨酸, BioXtra, ≥99% (titration)
Sigma-Aldrich
甘氨酸, ACS reagent, ≥98.5%
Sigma-Aldrich
甲醇, puriss., meets analytical specification of Ph Eur, ≥99.7% (GC)
Supelco
甘氨酸, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
甘氨酸, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance)
Sigma-Aldrich
3-吗啉丙磺酸, BioUltra, for molecular biology, ≥99.5% (titration)